Wells Fargo & Company MN lifted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 15.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,711 shares of the company's stock after purchasing an additional 7,149 shares during the period. Wells Fargo & Company MN owned 0.09% of argenx worth $32,417,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of ARGX. Steward Partners Investment Advisory LLC lifted its position in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after buying an additional 20 shares in the last quarter. SG Americas Securities LLC raised its stake in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC lifted its holdings in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares in the last quarter. Dynasty Wealth Management LLC boosted its position in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after purchasing an additional 22 shares during the period. Finally, Choreo LLC increased its stake in shares of argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company's stock worth $342,000 after purchasing an additional 23 shares in the last quarter. 60.32% of the stock is owned by institutional investors.
argenx Trading Down 1.7 %
argenx stock traded down $10.36 during trading on Wednesday, hitting $595.02. The company had a trading volume of 80,248 shares, compared to its average volume of 307,977. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The company's 50 day simple moving average is $605.51 and its 200-day simple moving average is $604.95. The stock has a market cap of $36.15 billion, a price-to-earnings ratio of -676.16 and a beta of 0.60.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have commented on ARGX. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Wedbush reissued an "outperform" rating and issued a $715.00 price target on shares of argenx in a report on Friday, April 11th. Piper Sandler increased their price objective on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a report on Tuesday, January 7th. Truist Financial reiterated a "buy" rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $690.33.
Read Our Latest Stock Report on argenx
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
